종합 대사 패널 검사 시장 : 검사 유형별, 적응 질환별, 최종사용자별 : 세계 기회 분석과 산업 예측(2023-2032년)

Comprehensive Metabolic Panel Testing Market By Test Type, By Disease Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,995,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,395,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

종합 대사 패널 검사 시장은 2022년에 101억 달러에 달하며, 2023-2032년의 CAGR은 4.8%를 기록하며, 2032년까지는 161억 달러에 달할 것으로 예측되고 있습니다.

종합 대사 패널(CMP)은 혈액내 여러 물질을 측정하는 혈액 검사입니다. 종합 대사 패널 검사는 혈중 당 수치를 나타내는 포도당 수치를 측정하여 당뇨병을 진단하고 기존 질환을 모니터링하는 데 사용됩니다. CMP 검사에는 나트륨, 칼륨, 염화물과 같은 전해질 검사도 포함됩니다. 이러한 전해질은 체액 균형을 유지하고 수축력과 같은 신경 및 근육 기능을 정상적으로 유지하는 데 중요합니다.

또한 CMP 검사는 개인의 혈액내 요소질소(BUN)와 크레아티닌의 양을 측정하여 신장 기능을 연구하고 신장 문제를 조기에 발견하는 데 기여합니다. 예를 들어 알라닌 아미노전이효소(ALT)와 아스파르트산 아미노전이효소(AST)는 모두 간내 손상이나 질병 발생을 보여줌으로써 간 건강 상태를 검사합니다. 전체적으로 종합 대사 패널은 주요 생리적 과정에 대한 종합적인 개요를 제공하여 의료 전문가가 다양한 건강 상태를 진단하고 관리하는 데 도움을 줍니다.

종합 대사 패널 검사 시장의 성장을 가속하는 요인으로는 진단 서비스에 대한 수요 증가와 CMP 검사와 같은 정확하고 시기적절한 진단 툴이 필요한 당뇨병, 심혈관 질환, 뇌졸중과 같은 만성질환을 들 수 있습니다. 예를 들어 미국 질병예방통제센터(CDC)에 따르면 2022년까지 미국 성인 10명 중 6명이 당뇨병을 앓게 될 것이라고 합니다. 이처럼 당뇨병, 심혈관 질환, 신장 질환과 같은 질병의 유병률 증가는 정기적인 생검을 필요로 하며 시장 성장을 가속할 것입니다.

또한 높아진 의료 인식과 검진 프로그램은 종합적인 대사 패널(CMP) 검사의 필요성에 크게 기여하고 있습니다. 공중보건 노력에서 예방적 건강관리의 중요성이 높아짐에 따라 정기적인 검진의 이점을 사람들에게 알리는 것이 중요한 요소로 작용하고 있습니다. 이러한 제도는 조기 발견과 조기 개입을 촉진하기 때문에 건강관리에 대한 적극적인 관리 습관이 형성되어 시장 성장을 가속하고 있습니다. 또한 예방적 건강관리로의 전환은 종합적인 대사 패널 검사 시장의 성장을 가속하는 중요한 요인입니다. 헬스케어가 발전함에 따라 신속한 헬스케어와 조기 진단에 대한 중요성이 강조되고 있으며, 이러한 추세는 개인이 정기적인 건강 검진을 도입하고 더 심각한 상황이 나타나기 전에 잠재적인 건강 위험을 식별하는 데 우선 순위를 두어 시장 성장을 가속하고 있습니다.

또한 노인 인구 증가로 인해 헬스케어 및 진단 검사의 필요성이 증가하고 있습니다. 노인들은 당뇨병, 심장병, 신장 질환과 같은 만성질환에 걸릴 확률이 높기 때문에 전반적인 건강 상태를 모니터링하고 만성질환을 관리하기 위해 종합적인 대사 프로그램을 통해 더 자주 건강 검진을 받아야 하는 경우가 많습니다. 종합적인 생화학적 정보를 제공하는 종합적인 조직 검사는 노인의 건강 유지와 질병 관리에 있으며, 매우 중요합니다.

그러나 개인과 의료 서비스 프로바이더 모두의 인식 부족은 종합적인 대사 패널 검사 분야의 확장에 큰 걸림돌로 작용하고 있습니다. 또한 헬스케어 비즈니스의 엄격한 규제 요건과 규정 준수 기준은 검사실과 진단 서비스 프로바이더에 어려움을 가져와 시장 성장에 걸림돌이 되고 있습니다. 반면, 현장 검사(Point-of-Care) 검사의 확대는 현장에서 빠른 결과를 제공하여 의료 전문가에게 편리함과 빠른 의사결정을 제공합니다. 특히 분산된 의료 환경에서 CMP 검사를 현장 진료 솔루션의 일부로 도입하는 것은 시장 성장에 유리한 기회를 제공할 수 있습니다.

종합 대사 패널 검사 시장은 검사 유형, 적응증 질환, 최종사용자, 지역별로 분류됩니다. 검사 유형별로 시장은 단백질, 전해질, 신장 검사, 간 검사, 기타로 분류됩니다. 적응증별로는 신장질환, 간질환, 당뇨병, 기타로 분류됩니다. 최종사용자에 따라 병원, 진단 실험실, 기타로 분류됩니다.

이해관계자를 위한 주요 이점

• 이 보고서는 2022-2032년 종합적인 대사 패널 검사 시장 분석 시장 부문, 현재 동향, 추정 및 역학에 대한 정량적 분석을 제공하여 우세한 종합적인 대사 패널 검사 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 종합 대사 패널 검사 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 종합 대사 패널 검사 시장 동향, 주요 기업, 시장 부문, 용도 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서의 커스터마이징이 가능합니다(추가 비용 및 일정에 대해는 영업 담당자에게 문의해 주십시오)

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 크리스 크로스 부문 분석 - 시장 규모 및 예측
• 기업 개요 확장 리스트
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 주요 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 종합 대사 패널 검사 시장 : 검사 유형별

• 개요
• 단백질
• 전해질
• 신장 검사
• 간 검사
• 기타

제5장 종합 대사 패널 검사 시장 : 적응 질환별

• 개요
• 신장 질환
• 간질환
• 당뇨병
• 기타

제6장 종합 대사 패널 검사 시장 : 최종사용자별

• 개요
• 병원
• 진단 연구소
• 기타

제7장 종합 대사 패널 검사 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • GCC
  • 남아프리카공화국
  • 북아프리카
  • 기타 중동 및 아프리카

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Quest Diagnostics
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche Ltd.
• ARUP Laboratories
• Walk-In Lab, LLC.
• Applied InGENuity Diagnostics
• Scion Lab Services, LLC
• Baptist Health
• My Care Labs
• Blueprint Genetics

KSA

영문 목차

영문목차

The comprehensive metabolic panel testing market was valued at $10.1 billion in 2022 and is projected to reach $16.1 billion by 2032, registering a CAGR of 4.8% from 2023 to 2032. The comprehensive metabolic panel (CMP) is a blood test that measures several substances in the blood. The comprehensive metabolic panel test measures glucose levels, which indicates the level of sugar in the blood and is used to diagnose diabetes or monitor existing cases. In addition, CMP tests include testing of electrolytes such as sodium, potassium and chloride, which are crucial in maintaining fluid balance and carrying out proper nerve and muscle function such as contractility.

Furthermore, CMP studies kidney operations through determination of varying amounts of urea nitrogen (BUN) and creatinine in individual's blood contributes early detection of renal problems which drives the demand for CMP testing and supports market growth. For instance, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both examine liver health by indicating damage or illness occurrence within it. Overall, a comprehensive metabolic panel provides a comprehensive overview of key physiological processes, aiding healthcare professionals in diagnosing and managing various medical conditions.

Factors driving the growth of the comprehensive metabolic panel testing market include increased demand for diagnostic services and chronic conditions such as diabetes, cardiovascular diseases, and stroke that require accurate equipment timely diagnostic tools such as CMP testing essential. For instance, according to the Centers for Disease Control and Prevention (CDC), by 2022, 6 out of 10 adults in the U.S. had diabetes. Thus, the rise in prevalence of conditions such as diabetes, cardiovascular diseases, and kidney diseases requires regular biopsies, which drives the growth of the market.

In addition, rise in health care awareness and screening programs contribute significantly to the need for comprehensive metabolic panel (CMP) test. As preventive healthcare becomes more important in public health initiatives, they have become key components in educating people on the benefits of routine check-ups. These schemes promote early recognition and intervention, thus cultivating proactive management practices regarding healthcare, which fuels market growth. Furthermore, the shift toward preventive healthcare is a key factor driving the comprehensive metabolic panel testing market growth. As healthcare evolves, with a surge in emphasis on prompt healthcare and early diagnosis, this trend encourages individuals to adopt regular health screenings, prioritizing the identification of potential health risks before they manifest in more severe situations, thereby driving market growth.

Moreover, the growing elderly population demands the need for health care and diagnostic testing. Older individuals often require more frequent health check-ups with a comprehensive metabolic program to monitor their overall health and manage chronic conditions as older people are more likely to develop chronic conditions such as diabetes, heart disease and kidney disease. Comprehensive histology, which provides comprehensive biochemical information, is important in maintaining the health of older people and managing these conditions.

However, a lack of awareness among both individuals and healthcare providers poses a significant obstacle to the expansion of the comprehensive metabolic panel testing sector. In addition, stringent regulatory requirements and compliance standards in the healthcare business provide difficulties for laboratories and diagnostic service providers thereby hampering market growth. In contrast, the expansion of point-of-care testing allows for rapid on-site results, providing convenience and quick decision-making for healthcare professionals. Developing and adopting CMP testing as part of point-of-care solutions, particularly in decentralized healthcare settings, provides lucrative opportunity for market growth.

The comprehensive metabolic panel testing market is segmented on the basis of test type, disease indication, end user, and region. By test type, the market is classified into proteins, electrolytes, kidney tests, liver test, and others. By disease indication the market is categorized into kidney diseases, liver diseases, diabetes, and others. By end user, it is segregated into hospitals, diagnostic laboratories, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the comprehensive metabolic panel testing market are Quest Diagnostics, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Blueprint Genetics, ARUP Laboratories, Walk-In Lab, LLC., Applied InGENuity Diagnostics, Scion Lab Services, LLC, Baptist Health, and My Care Labs. Key players have adopted acquisition, product approval and product launch as key developmental strategies to improve the product portfolio of the comprehensive metabolic panel testing market.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the comprehensive metabolic panel testing market analysis from 2022 to 2032 to identify the prevailing comprehensive metabolic panel testing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the comprehensive metabolic panel testing market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global comprehensive metabolic panel testing market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

• Proteins
• Electrolytes
• Kidney Tests
• Liver Tests
• Others

By Disease Indication

• Kidney Diseases
• Liver Diseases
• Diabtes
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• Quest Diagnostics
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche Ltd.
• ARUP Laboratories
• Walk-In Lab, LLC.
• Applied InGENuity Diagnostics
• Scion Lab Services, LLC
• Baptist Health
• My Care Labs
• Blueprint Genetics

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY TEST TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Proteins
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Electrolytes
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Kidney Tests
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Liver Tests
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY DISEASE INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Kidney Diseases
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Liver Diseases
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Diabetes
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Diagnostic Laboratories
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: COMPREHENSIVE METABOLIC PANEL TESTING MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Test Type
  • 7.2.3. Market size and forecast, by Disease Indication
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Test Type
    • 7.2.5.1.2. Market size and forecast, by Disease Indication
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Test Type
    • 7.2.5.2.2. Market size and forecast, by Disease Indication
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Test Type
    • 7.2.5.3.2. Market size and forecast, by Disease Indication
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Test Type
  • 7.3.3. Market size and forecast, by Disease Indication
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Test Type
    • 7.3.5.1.2. Market size and forecast, by Disease Indication
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Test Type
    • 7.3.5.2.2. Market size and forecast, by Disease Indication
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Test Type
    • 7.3.5.3.2. Market size and forecast, by Disease Indication
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Test Type
    • 7.3.5.4.2. Market size and forecast, by Disease Indication
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Test Type
    • 7.3.5.5.2. Market size and forecast, by Disease Indication
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Test Type
    • 7.3.5.6.2. Market size and forecast, by Disease Indication
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Test Type
  • 7.4.3. Market size and forecast, by Disease Indication
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Test Type
    • 7.4.5.1.2. Market size and forecast, by Disease Indication
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Test Type
    • 7.4.5.2.2. Market size and forecast, by Disease Indication
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Test Type
    • 7.4.5.3.2. Market size and forecast, by Disease Indication
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Test Type
    • 7.4.5.4.2. Market size and forecast, by Disease Indication
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Test Type
    • 7.4.5.5.2. Market size and forecast, by Disease Indication
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Test Type
    • 7.4.5.6.2. Market size and forecast, by Disease Indication
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Test Type
  • 7.5.3. Market size and forecast, by Disease Indication
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Test Type
    • 7.5.5.1.2. Market size and forecast, by Disease Indication
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Test Type
    • 7.5.5.2.2. Market size and forecast, by Disease Indication
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Test Type
    • 7.5.5.3.2. Market size and forecast, by Disease Indication
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Test Type
    • 7.5.5.4.2. Market size and forecast, by Disease Indication
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Test Type
  • 7.6.3. Market size and forecast, by Disease Indication
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Test Type
    • 7.6.5.1.2. Market size and forecast, by Disease Indication
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Test Type
    • 7.6.5.2.2. Market size and forecast, by Disease Indication
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Test Type
    • 7.6.5.3.2. Market size and forecast, by Disease Indication
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Test Type
    • 7.6.5.4.2. Market size and forecast, by Disease Indication
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Quest Diagnostics
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Laboratory Corporation of America Holdings
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. F. Hoffmann-La Roche Ltd.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. ARUP Laboratories
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Walk-In Lab, LLC.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Applied InGENuity Diagnostics
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Scion Lab Services, LLC
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Baptist Health
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. My Care Labs
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Blueprint Genetics
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료